FDA Clears Corindus' CorPath GRX System in Peripheral Vascular Interventions
February 20, 2018—Corindus Vascular Robotics, Inc. announced that it has received 510(k) clearance from the US Food and Drug Administration for use of the company's CorPath GRX system in peripheral vascular interventions (PVIs). The CorPath GRX system broadens the capabilities of the CorPath robotic technology platform from exclusively treating coronary artery disease (CAD) to include peripheral artery disease (PAD). The CorPath system now provides robotic precision for both PVI and percutaneous coronary intervention (PCI) procedures.
In the company's announcement, Alan Lumsden, MD, commented, "My colleagues and I have seen first-hand how CorPath GRX can overcome the challenges of manual PCI and I am excited to apply the capabilities of robotics to effectively treat PAD patients."
Dr. Lumsden, who is Chief of the Department of Cardiovascular Surgery at Houston Methodist Hospital in Houston, Texas, continued, "As a training site for future robotic interventionalists, I look forward to teaching these techniques to further enhance the quality of care for patients with both CAD and PAD."
Joseph Ricotta, MD, added, "CorPath GRX enables me to provide transformational treatment options to my patients suffering from PAD. As a long-time adopter of robotics, I am passionate about the opportunity this technology presents to advance endovascular care while providing a safer work environment for health care providers." Dr. Ricotta is Medical Director of Vascular Surgery and Endovascular Therapy, Tenet Healthcare; Professor of Surgery, Charles E. Schmidt College of Medicine at Florida Atlantic University in Boca Raton, Florida.